QC
LGND icon

Quadrature Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Quadrature Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$548K Buy
+1,734
New +$409K ﹤0.01% 976
2025
Q4 		– Sell
-1,487
Closed -$263K – 1491
2025
Q3 		$263K Sell
1,487
-1,569
-51% -$233K ﹤0.01% 704
2025
Q2 		$348K Buy
+3,056
New +$327K 0.01% 659

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's LGND Position: Q2 2026 in Review

Quadrature Capital opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,734 shares worth $548K. The stake represents ﹤0.01% of the portfolio and ranks #976 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in LGND as recently as Q3 2025.

Quadrature Capital first reported a position in LGND in Q2 2025 and has held it in 3 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Quadrature Capital held 1,734 shares of Ligand Pharmaceuticals worth $548K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Quadrature Capital position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #976 holding.
  • Quadrature Capital first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.